Efficacy and Tolerability of the Long-Acting Somatostatin Analog Lanreotide in Acromegaly. A 12-Month Multicenter Study of 58 Acromegalic Patients

[1] Melmed S(1995)Clinical review 75: Recent advances in pathogenesis, diagnosis, and management of acromegaly J Clin Endocrinol Metab 80 3395-3402

[2] Ho K(1992)Surgical management of acromegaly Endocrinol Metab Clin NorthAm 21 669-692

[3] Klibanski A(1992)Radiation therapy of acromegaly Endocrinol Metab Clin North Am 21 693-712

[4] Reichlin S(1997)Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly J Clin Endocrinol Metab 82 3187-3191

[5] Thorner M.(1996)Octreotide N Engl J Med 334 246-254

[6] Fahlbusch R(1993)Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours Clin Pharmacokinet 25 375-391

[7] Honegger J(1997)Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly Drugs 53 681-699

[8] Buchfelder M.(1990)Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients J Clin Endocrinol Metab 71 391-397

[9] Eastman RC(1991)Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide Arch Intern Med 151 1573-1578

[10] Gorden P(1992)Octreotide treatment of acromegaly. A randomized, multicenter study Ann Intern Med 117 711-718

[1] Melmed S(1995)Clinical review 75: Recent advances in pathogenesis, diagnosis, and management of acromegaly J Clin Endocrinol Metab 80 3395-3402

[2] Ho K(1992)Surgical management of acromegaly Endocrinol Metab Clin NorthAm 21 669-692

[3] Klibanski A(1992)Radiation therapy of acromegaly Endocrinol Metab Clin North Am 21 693-712

[4] Reichlin S(1997)Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly J Clin Endocrinol Metab 82 3187-3191

[5] Thorner M.(1996)Octreotide N Engl J Med 334 246-254

[6] Fahlbusch R(1993)Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours Clin Pharmacokinet 25 375-391

[7] Honegger J(1997)Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly Drugs 53 681-699

[8] Buchfelder M.(1990)Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients J Clin Endocrinol Metab 71 391-397

[9] Eastman RC(1991)Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide Arch Intern Med 151 1573-1578

[10] Gorden P(1992)Octreotide treatment of acromegaly. A randomized, multicenter study Ann Intern Med 117 711-718